Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vital Farms Inc (VITL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vital Farms Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Vital Farms Inc trades at $12.66 (market cap $554.89M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 71.9× Vital Farms Inc's market cap. Which is the better fit depends on your goals.
| ALNY | VITL | |
|---|---|---|
Market Cap | $39.89B | $554.89M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $52.41 |
52-Week Low | $278.09 | $8.28 |
Enterprise Value | $38.15B | $557.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Vital Farms (VITL) trades at $12.95, down 0.08% on the day, with a bullish technical signal supported by moving averages but overbought RSI readings. The stock shows solid profitability with a 6.1% net margin and 15.44% ROE, though earnings missed expectations in two recent quarters. Valuation appears reasonable with a P/E of 12.45 and P/S of 0.75. Recent news highlights volatility, including a class-action lawsuit filed in May 2026, while cash flow trends indicate significant investing outflows.
The outlook is mixed: analyst consensus leans bullish with a $13.50 price target, but risks include legal overhangs, earnings volatility, and negative cash flow. Revenue growth is modest, projected at $784M for 2026, but profit margins are declining. Investors should weigh strong fundamentals against near-term headwinds from litigation and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
